Report : Asia-Pacific ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)
At 3.9% CAGR, the Asia-Pacific ECMO Market is speculated to be worth US$ 139.19 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia-Pacific ECMO market was valued at US$ 110.85 million in 2022 and is expected to reach US$ 139.19 million by 2028, registering a CAGR of 3.9% from 2022 to 2028. Growing adoption of ECMO in lung transplantation procedures and increasing survival rates with ECMO are the critical factors attributed to the Asia-Pacific ECMO market expansion.
Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life. ECMO is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods. It acts as a bridge in patient undergoing lung transplantation. Therefore, the adoption of ECMO during lung transplantation is growing rapidly to manage patients with life-threatening lung disease. Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant. Thus, ECMO is used penultimately in treating PGD post lung transplantation. Thus, the demand for ECMO equipment is driving Asia-Pacific ECMO market.
On the contrary, complications associated with ECMO hurdles the growth of Asia-Pacific ECMO market.
Based on modality, the Asia-Pacific ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held 40.4% market share in 2022, amassing US$ 44.80 million. It is projected to garner US$ 58.43 million by 2028 to expand at 4.5% CAGR during 2022–2028.
Based on application, the Asia-Pacific ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held 55.4% market share in 2022, amassing US$ 61.44 million. It is projected to garner US$ 75.41 million by 2028 to expand at 3.5% CAGR during 2022–2028.
Based on age group, the Asia-Pacific ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held 43.3% market share in 2022, amassing US$ 48.00 million. It is projected to garner US$ 62.14 million by 2028 to expand at 4.4% CAGR during 2022–2028.
Based on country, the Asia-Pacific ECMO market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Our regional analysis states that China captured 29.8% market share in 2022. It was assessed at US$ 33.00 million in 2022 and is likely to hit US$ 42.59 million by 2028, exhibiting a CAGR of 4.3% during the forecast period.
Key players dominating the Asia-Pacific ECMO market are ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group among others.
- In May 2022, LivaNova PLC Acquired ALung Technologies, Inc. ALung Technologies, Inc., is a provider of low-flow extracorporeal carbon dioxide removal technologies for treating patients with acute respiratory failure.
- In April 2020, Abiomed acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. With the acquisition of Cardiopulmonary Support Technology (ECMO), the company expanded its product portfolio.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org